Pamrevlumab for idiopathic pulmonary fibrosis

JAMA

2024-05-19

(Press-News.org) About The Study: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in forced vital capacity from baseline to week 48.

Quote from corresponding author, Ganesh Raghu, M.D.:

“Current treatment with the two drugs approved by regulatory agencies for the treatment of idiopathic pulmonary fibrosis (IPF) merely slow the rate of lung function decline and are associated with adverse events that affect medication adherence. Because of the high mortality rates that are associated with IPF, the need for efficacious treatments that meaningfully improve patients’ feeling and function, as well as survival, is evident and unmet.

“This well-conducted, multinational phase 3 trial undertaken to assess the efficacy and safety of pamrevlumab for patients with IPF failed to confirm it. Despite the disappointment with the negative results, the success lies in the patients who participated in this trial and adhered to the protocol amid all the challenges and hurdles of the COVID-19 pandemic and lessons gleaned will help better design of future trials.”

Contact information for Ganesh Raghu, M.D.: email graghu@uw.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2024.8693)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8693?guestAccessKey=822f31af-46d7-4bed-b18f-275b80c4c704&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

END

ELSE PRESS RELEASES FROM THIS DATE:

Acetaminophen for prevention and treatment of organ dysfunction in critically ill patients with sepsis

2024-05-19

About The Study: In critically ill sepsis patients, treatment with intravenous acetaminophen for 5 days was safe but did not improve the primary end point of days alive and free of any organ support (dialysis, assisted ventilation, and vasopressors) to day 28 compared with placebo. Corresponding Author: To contact the corresponding author, Lorraine B. Ware, M.D., email Lorraine.ware@vumc.org. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2024.8772) Editor’s Note: Please see the ...

Measuring lung function more accurately and more equitably

2024-05-19

Removing race from equations that estimate lung function will shift the categorization of disease severity across patient populations, moving more Black individuals into an advanced disease category, according to new research led by scientists at Harvard Medical School. At the same time, more white and Hispanic people would be reclassified as having less advanced illness. The findings, the research team said, suggest that adjusting lung function tests to include race — as has been the case historically — likely normalized worse lung function and downplayed disease severity among Black people. The work, to be published May 19 in the New England Journal ...

Study reports ‘excellent’ outcomes for patients receiving optimized treatment for atrial fibrillation

2024-05-18

Atrial fibrillation (AF) is the most common form of arrythmia or irregular heartbeat worldwide, impacting millions of people in the U.S. alone. In a new study published in Heart Rhythm, researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, analyzed real-world clinical data to measure the impact of evidence-based best-practices on patient outcomes for the most common AF procedure: radiofrequency (RF)-based ablation. One year after the procedure, 81.6 percent ...

Modular Communicative Leadless ICD is safe and exceeds performance expectations

2024-05-18

Wireless implantable cardioverter-defibrillators (ICDs) eliminate the lead-related complications that come with a wired ICD, but they are unsuitable for patients with ventricular tachycardia, when the heart beats too quickly, or bradycardia, when the resting heart rate is seen as low. Research led by Amsterdam UMC, that is published today in the New England Journal of Medicine, shows that the first wireless modular system suitable for these patient groups is safe and exceeds performance expectations. Opening the door for a wider ...

Patients seen by female gastroenterologists have significantly less health care utilization than patients seen by male providers

2024-05-18

WASHINGTON, DC (May 18, 2024) — Patients seen by a female gastroenterologist for an initial consultation are less likely to use medical care in the emergency department, hospital or primary care office for two years after their visit when compared to patients initially seen by male gastroenterologists, according to a study to be presented at Digestive Disease Week® (DDW) 2024. “If there really is something different about the way female and male gastroenterologists provide care that impacts patient outcomes, it will be important to share these learnings broadly among health care providers ...

Iso-propagation vortices: optical multiplexing for unprecedented information capacity

2024-05-17

The future of optical communications just got brighter. In a groundbreaking development reported in Advanced Photonics, researchers from Nanjing University have introduced iso-propagation vortices (IPVs), a novel concept that offers a solution to a long-standing challenge faced by scientists and engineers: how to increase information processing capacity while overcoming the limitations of traditional vortex beams. Challenge: divergence and beam size Multiplexing of optical degrees of freedom, such as polarization and wavelength, has been a staple in enhancing communication capacity. ...

Ukraine blackouts caused by malware attacks warn against evolving cybersecurity threats to the physical world

2024-05-17

On a cold winter night in 2016, Ukrainians experienced the first-ever known blackout caused by malicious code (malware) designed to autonomously attack the power grid. One-fifth of Kyiv’s citizens were plunged into darkness as attackers used malware to target the capital city’s power grid. Six years later, in the early months of the ongoing Russia-Ukraine war, a second attack attempted to combine kinetic and cyber attacks to take down Ukraine’s power grid. Malware attacks against physical ...

How memories crystallize over time

2024-05-17

“Practice makes perfect” is no mere cliché, according to a new study from researchers at The Rockefeller University and UCLA. Instead, it’s the recipe for mastering a task, because repeating an activity over and over solidifies neural pathways in your brain. As they describe in Nature, the scientists used a cutting-edge technology developed by Rockefeller’s Alipasha Vaziri to simultaneously observe 73,000 cortical neurons in mice as the animals learned and repeated a given task over two weeks. The study revealed that memory representations transform from unstable to solid in ...

Gilbert Family Foundation invests $21 million to launch new research initiative focused on developing advanced disease models to accelerate cure for neurofibromatosis

2024-05-17

New initiative, launched on World NF Awareness Day, focuses on developing improved models to understand neurofibromatosis type 1 (NF1) with the goal of rapidly testing new treatments. 18 grants will be provided to leading medical research institutions in the United States and Europe. The Next-Generation NF1 Models Initiative is the Foundation’s fourth research initiative focused on accelerating a cure for neurofibromatosis. DETROIT, May 17, 2024 – Gilbert Family Foundation, a private foundation established by Dan and Jennifer Gilbert to accelerate a cure for ...

Multiple onychopapillomas and BAP1 tumor predisposition syndrome

2024-05-17

About The Study: This study found that BRCA1-associated protein (BAP1) tumor predisposition syndrome was associated with a high rate of nail abnormalities consistent with onychopapillomas (a benign tumor of the nail) in adult carriers of the disease. Findings suggest that this novel cutaneous sign may facilitate detection of the syndrome in family members who are at risk and patients with cancers associated with BAP1 given that multiple onychopapillomas are uncommon in the general population and may be a distinct clue to the presence of a pathogenic germline variant in the BAP1 gene. Corresponding Authors: To contact the corresponding authors, ...

UT Health San Antonio awarded $3 million in CPRIT grants to bolster cancer research and prevention efforts in South Texas

Manhattan E. Charurat, Ph.D., MHS invested as the Homer and Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine

Insilico Medicine’s Pharma.AI Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence

Nanoplastics have diet-dependent impacts on digestive system health

Brain neuron death occurs throughout life and increases with age, a natural human protein drug may halt neuron death in Alzheimer’s disease

University of Phoenix College of Doctoral Studies releases white paper on AI-driven skilling to reduce burnout and restore worker autonomy

Ending federal support for housing first programs could increase U.S. homelessness by 5% in one year, new JAMA study finds

New research uncovers molecular ‘safety switch’ shielding cancers from immune attack

[Press-News.org] Pamrevlumab for idiopathic pulmonary fibrosis
JAMA

Pamrevlumab for idiopathic pulmonary fibrosis

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: